# iPSC: one cell line, every dose

What the Yamanaka reset preserves and destroys, why chemically defined media decide batch comparability, and where human-iPSC assays replace animal studies.

Reprogramming turned stem cells from a scarcity into a supply chain; the field's real product is the defined medium that makes two batches grow the same.

Source: https://en.bioecon.ru/docs/health-biomedicine/regenerative-personalized/induced-pluripotent-stem-cells-ipsc/
Updated: 2026-09-22



Induced pluripotent stem cells are made by convincing a specialized cell that it was never specialized at all. The reprogramming factors overwrite the epigenetic marks of a skin cell or blood cell until the genome behaves like an embryonic one - self-renewing indefinitely, ready to become anything. What the reset keeps is the donor's genotype; what it restores is developmental possibility; and what it cannot restore is the cell's age-associated damage, which is why the field measures reprogramming by what survives, not only by what appears.
The canonical reset uses four transcription factors - OCT4, SOX2, KLF4 and c-MYC - first delivered by retroviral integration. Integration leaves scars in the genome, so manufacturing-grade lines are now reprogrammed by non-integrating systems: Sendai virus, episomal vectors, synthetic mRNA. Every bank is then quality-controlled against what the process can do wrong - karyotype drift, copy-number changes acquired in culture, residual undifferentiated cells that would carry teratoma risk into an infusion product - and release assays for residual pluripotency markers are the control on the one failure mode this platform cannot tolerate.
The industrial secret of the platform is the medium. A stem cell is only as reproducible as the chemistry it grows in, and early iPSC work grew on undefined serum and feeder layers that made every batch a small experiment. Chemically defined formulations - the HiDef class tested across more than a hundred hiPSC and hESC lines - turned expansion into a specification: suspension culture, xeno-free components, lot-to-lot consistency. Once growth is specified, the master cell bank becomes what its name promises - a fixed reference from which every therapy batch and every assay plate descends, traceable lot by lot. The ledger's manufacture exemplar is an iPSC-NK program producing standard batches from a single engineered line inside a 40,000-square-foot GMP suite in San Diego, state-licensed, with FDA INDs and MHRA and EMA interactions - the banked-line model in production form.
The regulatory frontier is the most consequential use. Human iPSCs let developmental toxicology run on human cells rather than surrogate species, and an assay with an FDA-agreed Context of Use under ICH S5(R3) is not a research tool but a decision instrument: a candidate drug fails earlier, in a dish, for a reason an agency has pre-agreed to read. Two caveats bound the platform honestly. Clones from the same donor line are not interchangeable - reprogramming preserves epigenetic memory of the source cell, and clone-to-clone variation in differentiation behavior is documented in the field's own comparisons. And long-term genomic stability over extended expansion remains an open question the field itself flags, which is why bank age and passage number stay on the specification sheet.
The boundary against sibling pages follows the platform: stem-cell therapy applications and personalized regenerative medicine own the clinical deployments; this page owns the reprogramming, the media chemistry and the assays that make those deployments manufacturable.